Latest 8-K filings

OMNIQ Corp. announced two municipal agreements in Pennsylvania for its Q Shield Safe City platform, marking entry into a new state with a recurring revenue model.

Global Business Travel Group, Inc. (Amex GBT) announced the completion of its acquisition by Long Lake Management for approximately $6.3 billion, delisting from the NYSE to operate as a private entity.

CareCloud, Inc. announced the promotion of Bonnie Boyer to Chief Financial Officer, effective October 1, 2026, succeeding Norman Roth who will transition to Advisor to the CEO.

Host Digital Inc. CEO Harmol Samra issued a letter to shareholders detailing the company's new direction in data center development for AI and HPC following its recent merger and public listing.

Nauticus Robotics, Inc. has secured a waiver for a September 30, 2026, triggering event related to its Series C Convertible Preferred Stock, extending the waiver period to December 31, 2027.

Ensysce Biosciences, Inc. filed an amendment to its Series C Preferred Stock Certificate of Designation, removing a specific redemption clause.

OneMedNet Corporation is implementing a 1-for-10 reverse stock split to comply with Nasdaq's minimum bid price requirement and aims to broaden investor interest.

PRA Group announces a proposed $400 million offering of senior notes due 2033 to refinance existing credit facility borrowings.

NewAmsterdam Pharma has dosed the first participant in its Phase 2b SPINOZA clinical trial evaluating obicetrapib for preclinical Alzheimer's disease.

The PNC Financial Services Group, Inc. announced the redemption of $525 million in Depositary Shares representing interests in its Series S Preferred Stock.

Flash Sports & Media Holdings, Inc. has entered into a significant agreement with MindWave Innovations Inc. to develop and operate FlashChain, a blockchain network aimed at revolutionizing digital broadcasting rights, asset tracking, and fan engagement.

Alaska Air Group detailed its 'activation' phase of the Alaska Accelerate plan, focusing on premium experiences, global connectivity, loyalty, and cargo to drive future earnings.

Keros Therapeutics announced it will receive a $20 million development milestone payment from Takeda following the first patient dosing in the Phase 3 ELRiSE MF clinical trial for elritercept.

First United Corporation announced the election of Steven R. Stuck, Shawn Bender, and Nina Beitzel to its Board of Directors, effective September 24, 2026.

Top Financial Group Limited has amended appointment letters for its independent non-executive directors, shifting compensation from a mix of cash and shares to entirely cash-based.

Imunon, Inc. has entered into an Exchange Agreement to convert $1.2 million of its A-1 Note principal into Series B Preferred Stock, impacting its capital structure.

SurgePays, Inc. has received an additional 180-day extension from Nasdaq to regain compliance with the minimum $1.00 bid price requirement, now until March 22, 2027.

Bloomin Brands, Inc. has successfully amended and restated its revolving credit facility, extending the maturity date to September 25, 2031, while maintaining existing commitments and pricing.

Allarity Therapeutics announced the expansion of its in-house medical laboratory to include proteomics and cell line research, enhancing its capabilities for drug development and external partnerships.

Atossa Therapeutics announced a plan to issue contingent value rights (CVRs) to shareholders, entitling them to 25% of net proceeds from the monetization of a rare pediatric disease priority review voucher, up to a $50 million cap.

TransDigm Inc. has completed a $3 billion offering of 6.75% Senior Secured Notes due 2035, with proceeds intended for repurchasing existing debt and general corporate purposes.

Unicycive Therapeutics has resubmitted its New Drug Application for oxylanthanum carbonate, a phosphate binder for kidney disease patients, with an anticipated FDA decision within six months.

SoundThinking, Inc. has entered into a definitive merger agreement with Transom Capital Group, under which Transom will acquire the company for $8.00 per share in cash plus a contingent value right (CVR) of up to $3.00 per share.

Cartesian Therapeutics announced additional positive retreatment data for Descartes-08 in myasthenia gravis patients, showing deep and durable responses.

Invivyd announces positive topline results from its LIBERTY Phase 3 study for VYD2311, demonstrating superior safety and tolerability compared to an mRNA COVID-19 vaccine and paving the way for regulatory submission.

Aquestive Therapeutics announced the appointment of Richard J. Daly to its Board of Directors, effective October 14, 2026, strengthening its leadership with extensive life sciences executive experience.

JELD-WEN Holding, Inc. announced a comprehensive agreement to extend debt maturities and raise $135 million in new liquidity, aiming to strengthen its capital structure and support its business plan.

Iovance Biotherapeutics has increased its full-year 2026 revenue forecast to $410-$420 million, citing strong demand for Amtagvi and Proleukin.

The Sherwin-Williams Company has entered into a new $750 million senior unsecured term loan credit agreement, replacing its existing facility and providing flexibility for general corporate purposes.

1-800-Flowers.com, Inc. announced it has entered into a definitive agreement to sell its PersonalizationMall.com and Things Remembered businesses to PlanetArt, LLC for approximately $45 million in cash.